Amit M Oza

Amit M Oza, BSc, MD, MBBS, FRCPC

Dr. Amit Oza is a Senior Staff Physician and Professor of Medicine at the Princess Margaret Cancer Centre and the University of Toronto. He is cross-appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew's Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St. Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin's Disease. He is a Fellow of the Royal College of Physicians of London and Canada.

Dr. Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynecological cancer and advanced colorectal malignancies. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMH.

Dr. Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.

He is currently interim Head, Department of Medical Oncology & Hematology, Co-Director of the Robert and Maggie Bras and Family Drug Development Program at the Princess Margaret Cancer Centre. This is the largest new drug development program in Canada and the only center outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is Co-Chair for the Gynecological Cancer Steering Committee of the National Cancer Institute and represents the Princess Margaret Phase II Consortium at the Gynecologic Cancer InterGroup.

Gynecol Oncol. 2017 Sep 04;:
Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J,...
Lancet Oncol. 2017 Jul 25;:
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P, SOLO2/ENGOT-Ov21...
Int J Gynecol Cancer. 2017 Jul 07;:
Wilson MK, Friedlander ML, Lheureux S, Small W, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM
Cancer Discov. 2017 Jun 06;:
Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX...
Nat Commun. 2017 May 11;8:15086
Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, Pugh TJ
Oncotarget. 2017 Apr 10;:
Rafii S, Gourley C, Kumar R, Geuna E, Ang JE, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA
Expert Opin Pharmacother. 2017 Mar 16;:
Kanjanapan Y, Lheureux S, Oza AM
Clin Cancer Res. 2017 Mar 06;:
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R
Clin Cancer Res. 2017 Feb 21;:
Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson D, Timms KM, Lanchbury JS, Kaye SB, Gourley C, Bowtell DD, Kohn EC, Scott CL, Matulonis UA, Panzarella T, Karakasis K, Burnier JV, Gilks B, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW,...
J Clin Oncol. 2017 Feb 21;:JCO2016713677
Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM

Pages


 

Co-director, Robert and Maggie Bras and Family Drug Development Program​
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology